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Besides its scientific relevance this thesis also has implications for society as we identified and ad-
dressed hidden infections and evaluated current infectious disease prevention, surveillance and con-
trol. Based upon this thesis and recent literature we have several recommendations on how to improve 
current practice and policy. Overall, better insight into hidden infections allows for more targeted and 
effective testing practices in order to eventually protect the most vulnerable groups at risk. Several 
methodologies can be used to detect hidden infections. This thesis showed the value of the surveil-
lance pyramid as a tool to determine the different levels in infectious disease control and factors in-
fluencing its accuracy. Epidemiological and geographical analyses compliment each other in identify-
ing risk groups and estimating the prevalence of infectious diseases including hidden infections. 
However, there is no one-size-fits-all approach which can be applied to every infectious disease. Fur-
thermore, this thesis demonstrates the importance of examining models and estimates in a real-life 
setting.
Hidden pertussis infections
We were able to give more insight into the factors that hamper the identification of hidden pertussis 
infections. These findings function as an important input for the discussion on how to reduce the work-
load of Public Health Service (PHS) and the debate on how to reduce the overall delay until notification 
to improve pertussis control. Overall, it is likely that the identified misdiagnosis, under-notification and 
overall delay in surveillance data are not unique for this area of the Netherlands and are generalizable 
to the rest of Europe. These countries are likely to encounter varying guidelines, difficulties in pertussis 
diagnostics and unexplained local differences in notification data too. Ideally, the accuracy of surveil-
lance would be improved by focusing on the factors identified here. This contributes to optimisation of 
the surveillance system and more importantly, to improved pertussis control by preventing young in-
fants from being infected with pertussis and avoiding morbidity and mortality in this young group.
First, to reduce misdiagnosis and the variation in pertussis diagnostics, we recommend laborato-
ries and healthcare providers (HCPs) to improve adherence to national guidelines concerning timing 
and choice of test. For laboratories, a national uniform and standardised guideline on cut-off values in 
serology and the use of IgA and/or IgG is desirable. Testing all patients presenting with cough is not 
feasible, as only 3% of adult patients presenting with acute cough in primary care had evidence of an 
acute pertussis infection in Europe. Moreover, testing for pertussis follows to an extent the general 
healthcare seeking behaviour for common respiratory infections, whereas the current pertussis inci-
dence is largely the result of testing. Increased testing would thus not necessarily improve pertussis 
control. Therefore, HCPs should focus pertussis testing on family members surrounding incompletely 
vaccinated infants <1 year of age, women >34 weeks pregnant and children with severe comorbidities 
such as heart or lung failure. In addition, they are advised to check whether patients with symptoms 
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suggestive of whooping cough have vulnerable groups at risk in their household. As such, general 
practitioners (GPs) could play a more prominent role in contact tracing (now carried out by the PHS in 
the Netherlands) in order to minimise the disease burden in infants. We informed the GPs and labora-
tories in our region about our study results to remind them of the pertussis testing guidelines and to 
advise on possible preventive measures. 
Second, to reduce under-notification, medical microbiology laboratories and HCPs could benefit 
from introducing automated notification systems. In an endemic situation with severe underreporting, 
the obligatory notification of pertussis is not effective for the protection of unvaccinated children. On 
the other hand, the notification of pertussis infections is of great value to national policy on pertussis 
surveillance and control although we showed the limitations of pertussis surveillance. Pertussis has 
to remain a notifiable disease as it is necessary to prohibit a pertussis-positive patient to go to work 
when he/she works with vulnerable young infants. In this thesis, we showed that the detection of per-
tussis outbreaks using space-time cluster detection is feasible and could help to facilitate an early 
and appropriate public health response. However, this approach has to be adjusted for the strong de-
pendency to testing and is probably most efficient when using test-positivity as indicator.
Third, as public health is almost always too late to intervene, delays need to be reduced and we 
need earlier preventive measures by healthcare providers. Patient delays due to late presentation to 
healthcare may be unavoidable, however delays in reporting once a patient presents can be reduced. 
GPs, midwives and day nursery employees could play a major role here. Creating awareness among 
these professionals as well as patients themselves about taking timely preventive measures could 
lead to lower individual disease burden and to a higher cost-effectiveness of pertussis care. 
At last, we also need additional preventive measures for the most vulnerable and susceptible 
group of unvaccinated infants, as the Dutch national vaccination program starts at the age of two 
months. In the first few months, young infants are unprotected as vaccination is only effective after at 
least three doses. The efficacy of pertussis vaccines has been debated because of waning immunity, 
incomplete protection of infants below 5 months, genetic changes in Bordetella pertussis and limited 
duration of protection. Currently, maternal immunisation provides good protection against infant dis-
ease, whilst no important side effects were observed, and has been recommended by the World Health 
Organisation and the European Centre for Disease Prevention and Control. The Dutch health council 
advised the introduction of maternal vaccination to the national vaccination program (December 2015) 
and pertussis vaccinations for healthcare workers (June 2017). Maternal vaccination will be executed at 
the child healthcare centres and introduced to the national vaccination program in 2019. 
Hidden hepatitis infections
Lessons learned from our evidence-based practice to detect hidden hepatitis infections can be applied 
to future testing strategies and policy. The success factors of our high test uptake were the combina-
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tion of a personal invitation letter accompanied by reminder letters, the birth cohort testing, the hot-
spot approach and the cooperation between public health care and primary care. 
At first, as no active hepatitis C virus (HCV) infections were found in the identified hotspots, the 
hotspot strategy would probably not work in other areas of the Netherlands as well as other countries 
with low HCV prevalence. Our findings partly informed the Dutch Health Council in their advice against 
screening of the general Dutch population for HCV and HBV (November 2016). This advice is part of the 
national hepatitis elimination plan, developed by specialists, doctors of the public health service and 
GPs, aimed at the prevention of transmission and reduction of hepatitis related disease burden and 
deaths. The committee recommends case finding by GPs for people in risk groups and by institutions 
who are responsible for delivering care to people in risk groups or for accommodating these people. 
The GP guidelines in the UK and the Netherlands advice to focus more on targeted HBV testing, espe-
cially among non-western migrants as they account for the largest proportion of HBV and HCV infec-
tions. This is in line with the recommendation of the Dutch Health Council on regional HBV screening 
programmes in areas with relatively large groups of first-generation migrants from high-endemic 
countries (≥2% chronic HBV infection). In the Netherlands, people who inject drugs (PWID) and 
HIV-positive men who have sex with men are tested for HBV and/or HCV as part of comprehensive 
health care programs (i.e., HIV treatment, HBV vaccination, and harm reduction programs for PWID). 
However, for migrants there are no structural screening programs. This may partly be caused by the 
heterogeneity of this population, in terms of ethnic origin, risk for infection and awareness of infection 
status. Some screening interventions in the Netherlands have targeted different migrant groups. These 
interventions, however, were limited in geographical coverage, and uptake was often low/moderate 
depending on the screening model. Structural screening programs for (subgroups of) migrants are 
needed to substantially reduce chronic viral hepatitis related morbidity and mortality among migrants, 
and the sustainability, linkage to care and access to treatment has to be ensured. 
Additionally, our testing strategy could be applied to detecting HCV and HBV in high-endemic 
countries, to other infectious diseases and high-endemic settings. Higher positivity rates have been 
found in studies of countries with higher prevalence and in settings other than the general population 
with higher prevalence, such as the emergency department. An American study showed that HCV-in-
fected individuals are more likely to use the emergency department (ED) for care than any other health 
care setting. Testing in this setting reveals hidden infections as this testing could reach those who do 
not respond to screening projects, do not feel at risk or avoid health care in general. Furthermore, 
test-uptake in this setting may be very high as tests can be offered and performed within routine diag-
nostic work-up. Several studies in the UK and US support routine testing on HCV in the ED setting with 
high test-uptakes and anti-HCV prevalence. In the context of applicability, it is shown that routinely 
offering HCV testing to patients who are undergoing laboratory testing had no effect on length of stay 
at the emergency department.
Consciousness of health care providers, for example to prompt viral hepatitis testing when people 
present with abnormal liver function, is needed to identify those infected who do not belong to one of 
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the risk groups. Automated screening alerts for ALAT elevation (diagnostic liver enzyme) at the GP 
clinic can be a tool to detect hidden HCV infections, although this is a challenging process. The risk of 
HCV infection is substantially elevated in Dutch primary care patients with an ALAT elevation between 
50 IU/l and 100 IU/l, whereas the risk of HBV infection is not. Therefore, diagnostic follow-up for HCV is 
recommended in all these patients, particularly in those for whom no clear explanation for the ALAT 
elevation is found. Among HBV patients without an indication for referral, ALAT should be checked, 
both the GP and the patient should be reminded for these check-ups. 
Future projects aimed at detecting chronic HBV and HCV infections hidden to care in the Nether-
lands should focus on retrieval projects. This includes retracing and evaluating patients previously di-
agnosed with HBV or HCV who are eligible for treatment. In the Netherlands, there is evidence for pa-
tients diagnosed with HBV or HCV who are eligible for treatment still remain untreated. These patients 
were lost to follow-up as they stopped treatment because of the side effects, were not able to start 
treatment because of contra-indications, or did not attend their follow-up appointments. The Health 
Council of the Netherlands recommend retracing people who have been diagnosed with HBV or HCV in 
the past but are no longer receiving care. This retracing should focus on giving patients the opportuni-
ty to make use of the new treatment options. Once they have been retraced, they must promptly be 
given appropriate care. Studies on detection of chronic hepatitis B and C patients who were lost to 
follow up, enables evaluation of the indication for current treatment options.
Currently, a national registry of all HBV and HCV infected patients is in development and will in-
clude patients characteristics and treatment data. HBV infections and recent HCV infections are noti-
fiable diseases. Until now, chronic HCV infections are not notifiable. Therefore, there is no national 
surveillance system nor a database for chronic HCV infections. The surveillance of HCV could be im-
proved by introducing chronic HCV infections into the notification policy. This would also make the 
current HBV and HCV estimated prevalence more precise. 
We have provided scientific and societal relevance in the work presented. We identified and ad-
dressed hidden infections and evaluated current infectious disease prevention, surveillance and con-
trol. Based upon this work and recent literature we suggested on improvements of current practice 
and policy in hepatitis and pertussis control. Overall, better insight into hidden infections allows for 
more targeted and effective testing practices in order to eventually protect the most vulnerable groups 
at risk. Although, there is no one-size-fits-all approach we showed several methodologies that can be 
applied to the assessment of hidden infections in infectious diseases.
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